While multiple randomized, placebo controlled trials have now demonstrated that corticosteroids improve survival in patients with COVID-19,<sup>1, 2</sup> IL-6 inhibition, which gained significant early interest based on observational studies, has not demonstrated reliable efficacy in randomized, placebo controlled trials.<sup>3, 4</sup> To better understand the mechanistic basis of immunomodulatory therapies being implemented for treatment of COVID-19, we assessed longitudinal biochemical changes in response to such approaches in hospitalized patients with COVID-19. This evidence concerns the gene IL6 and COVID-19.